S-phase fraction as response marker in patients with chronic myeloid leukemia
- 1 January 2009
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 50 (7), 1223-1225
- https://doi.org/10.1080/10428190902995663
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response MonitoringHematology, 2006
- Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemiaCancer, 2004
- The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseCancer, 2003
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaThe New England Journal of Medicine, 2002
- Chronic Myeloid LeukemiaThe New England Journal of Medicine, 1999
- A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJNCI Journal of the National Cancer Institute, 1998
- Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathologyCytometry, 1993
- Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.Journal of Clinical Oncology, 1992
- Prognostic discrimination in "good-risk" chronic granulocytic leukemiaBlood, 1984
- Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.The Journal of cell biology, 1975